uniQure (NASDAQ:QURE) Stock Price Down 6.4% - Time to Sell?

Key Points

• uniQure's stock fell by 6.4% during trading, closing at $14.02 after previously trading at $14.98, reflecting a significant drop in trading volume.
• Analyst ratings are mixed, with six analysts rating the stock as buy and one as sell, indicating varying confidence levels in its future performance.
• The company recently reported a loss of $0.69 per share, outperforming analyst expectations, although it continues to show a negative net margin and return on equity.

uniQure N.V. (NASDAQ:QURE - Get Free Report) shares were down 6.4% during mid-day trading on Tuesday . The stock traded as low as $14.58 and last traded at $14.02. Approximately 179,634 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 1,391,692 shares. The stock had previously closed at $14.98.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Guggenheim reaffirmed a "buy" rating and set a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Cantor Fitzgerald raised uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Wall Street Zen lowered uniQure from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Price Performance

The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53. The stock has a market cap of $705.40 million, a PE ratio of -2.93 and a beta of 0.08. The business has a 50-day moving average price of $14.94 and a 200 day moving average price of $13.68.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,077.05% and a negative return on equity of 483.87%. As a group, research analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert Gut sold 3,336 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $48,205.20. Following the transaction, the director directly owned 56,879 shares in the company, valued at approximately $821,901.55. This represents a 5.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeannette Potts sold 4,670 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the sale, the insider owned 115,073 shares of the company's stock, valued at $1,742,205.22. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,144 shares of company stock worth $322,426. 4.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Vestal Point Capital LP boosted its position in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after buying an additional 1,767,572 shares during the last quarter. Nantahala Capital Management LLC grew its holdings in shares of uniQure by 3.8% in the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock worth $29,213,000 after acquiring an additional 101,598 shares during the period. Aberdeen Group plc increased its position in uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company's stock valued at $38,345,000 after acquiring an additional 535,163 shares during the last quarter. Avoro Capital Advisors LLC bought a new position in uniQure in the fourth quarter valued at about $38,410,000. Finally, Franklin Resources Inc. boosted its position in uniQure by 33.1% in the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after purchasing an additional 494,726 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.